Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation - PubMed
3 hours ago
- #Immunotherapy
- #Melanoma
- #Personalized Medicine
- Melanoma represents only 4% of skin cancers but causes 75% of skin cancer-related deaths, with rising incidence.
- Immune checkpoint blockades (ICBs) are a core systemic therapy for advanced melanoma, alongside targeted therapies and immunotherapies.
- Clinical use of ICBs is limited by immune-related toxicities, primary/acquired resistance, and inter-patient response heterogeneity.
- The review covers progress in understanding immune checkpoints in melanoma and outcomes from clinical trials of ICBs like CTLA-4, PD-1, and PD-L1 inhibitors.
- Personalized treatment approaches are emphasized to address diverse patient needs and improve outcomes.